Avara to buy ex Crestor API plant from AstraZeneca

By Gareth Macdonald

- Last updated on GMT

iStock/Choreograph
iStock/Choreograph

Related tags Astrazeneca

Avara Pharmaceutical Services will buy the UK manufacturing facility at which AstraZeneca made the API for Crestor and Seroquel.

The deal – financial terms of which were not disclosed – will see US based Avara buy the plant in Avlon, UK and take on 210 employees. The firm has also been contracted to supply AstraZeneca with active pharmaceutical ingredients (API).

The facility was earmarked for closure in 2008 when AstraZeneca said it would outsource production of the ingredients for blockbuster cardiovascular drug Crestor (rosuvastatin) and schizophrenia drug Seroquel (Quetiapine).

In 2014 AstraZeneca reiterated the closure plan and said it would wind up operations by 2017. At the time a spokesman told us “The majority of API manufacturing undertaken at Avlon will be outsourced once the site closes.”​ 

News of the deal comes less than a month after Avara said it is buying the contract manufacturing business of Japanese drug producer Astellas Pharma. The deal, financial terms of which were not disclosed, also saw Avara contracted to make products for Astellas.

Related news

Show more

Related products

show more

Increasing the Bioavailability of Oncology Drugs

Increasing the Bioavailability of Oncology Drugs

Content provided by Lonza Small Molecules | 13-Nov-2023 | White Paper

Oral tyrosine kinase inhibitors (TKIs) are a class of cancer drugs that can be highly susceptible to issues with solubility in the gastrointestinal tract

Efficient Freezing & Storage of Biopharmaceuticals

Efficient Freezing & Storage of Biopharmaceuticals

Content provided by Single Use Support | 06-Nov-2023 | White Paper

Various options exist for freezing biopharmaceutical bulk material, but selecting the most effective and efficient approach for each cold chain can be...

Manufacturing Drugs with Highly Potent APIs

Manufacturing Drugs with Highly Potent APIs

Content provided by Altasciences | 28-Sep-2023 | White Paper

In this issue of The Altascientist, we examine the critical considerations for the safe and compliant manufacture of drugs with highly potent APIs (HPAPIs),...

Follow us

Products

View more

Webinars